MENLO PARK, Calif., Sept. 2, 2014 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human growth hormone (rhGH), today announced that Jeffrey L. Cleland, PhD, Chief Executive Officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 9, 2014 at the Grand Hyatt New York in New York City.
|Event:||Morgan Stanley 2014 Global Healthcare Conference|
|Date:||Tuesday, September 9, 2014|
|Time:||2:55 p.m. EDT / 11:55 a.m. PDT|
An audio webcast of the Company's presentation will be available on the investor relations section of Versartis' website at www.versartis.com. A replay of the presentation will be available for 90 days.
About Versartis, Inc.
Versartis, Inc. is an endocrine-focused biopharmaceutical company initially developing VRS-317, a novel, long-acting form of recombinant human growth hormone, for the treatment of growth hormone deficiency (GHD). VRS-317 is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance and therefore treatment outcomes. The Company has recently completed a Phase 2a clinical trial evaluating weekly, semi-monthly and monthly dosing regimens of VRS-317 in children with GHD. Further information on Versartis can be found at www.versartis.com.
CONTACT: Corporate & Investors: Joshua Brumm Chief Financial Officer (650) 963-8582 IR@versartis.com Investors: Nick Laudico The Ruth Group (646) 536-7030 firstname.lastname@example.org Media: Debra Bannister Corporate Communications (530) 676-7373 email@example.com